Acute Myeloid Leukemia Coverage From Every Angle

Recent News

Optimal Number of Chemotherapy Courses for Younger Patients With AML
Testing for Germline Mutations in Elderly Patients With AML
Green Tea Treatment in Elderly Patients With Myelodysplasia-Related AML
Comparison of Hypomethylating Agent Plus Venetoclax With CPX-351 in Secondary AML
Predicting Response to Venetoclax Combination Therapy in Resistant AML
Revised Label Approved by FDA for Daunorubicin/Cytarabine Combination for AML
Case Report: Central Diabetes Insipidus and AML
Using Existing Drugs to Treat Unique Subtype of NPM1-Mutated AML
Phase II French Trial of Eprenetapopt Plus Azacitidine in AML
Prognostic Impact of IDH Mutational Status in AML After HSCT
Can Fractionated Myeloablative Busulfan Regimen Improve Outcomes in Older Patients With AML?
Could AML Progression Be Fueled by Chemotherapy-Induced Dormancy of AML Cells?
Is MRD Status Predictive of Survival in Resistant AML?
Association Between Pretransplant Molecular MRD and Outcomes in AML
Novel Combination Results in Anticancer ‘Double Whammy’ in AML
TCT 2021: Natural Killer Cell Therapy Under Study in Selected Patients With AML
TCT 2021: CPX-351 Versus Chemotherapy for High-Risk of Secondary AML
TCT 2021: Effects of HSCT After Azacitidine Therapy for AML
Does Exposure to Occupational Pesticides Increase the Risk for AML?
TCT 2021: JSP191 With Fludarabine and Total-Body Radiation in Older Adults With AML
Eprenetapopt Plus Azacitidine Under Study in TP53-Mutant AML
Decitabine Plus Venetoclax Versus Chemotherapy Among Older Patients With AML
Why Do Some Patients With Newly Diagnosed AML Decline Treatment?
Newly Diagnosed FLT3-Mutant AML: Sorafenib Plus Chemotherapy
Gilteritinib Plus Chemotherapy for Newly Diagnosed AML
Intravenous and Subcutaneous Cytarabine for Standard Induction Therapy in AML
Quizartinib-Based Triplet Therapy for FLT3-ITD–Mutated AML
5-Year Results for CPX-351 in Older Adults With High-Risk AML
Safety Profile of Midostaurin in Older Patients With AML
Oral Azacitidine as Maintenance Therapy for Acute Myeloid Leukemia
Race Matters Significantly in AML Outcomes, Study Data Show
ASH 2020: Phase III Trial of Gilteritinib Plus Azacitidine for FLT3-Mutated AML
ASH 2020: Gilteritinib Versus Salvage Chemotherapy for FLT3-Mutated AML
COVID-19 and Acute Leukemias: German Investigators Share Treatment Experiences
ASH 2020: Venetoclax Plus CPX-351 in AML
ASH 2020: Early Results in Targeting CD47 in AML
FDA Brief: Eprenetapopt Given Fast Track Designation for TP53-Mutant AML
Altered Bone Marrow Niche: Predicting Outcomes in AML?
Precision Medicine in AML Early Results From Beat AML Master Trial
Relapsed AML in Children and Hematopoietic Cell Transplantation
Predicting Low-Risk Febrile Neutropenia in Chemotherapy-Treated Patients With AML
Suicide Risk Factors for Patients With AML and Other Leukemias
Anti–TIM-3 Monoclonal Antibody Under Study in AML
Rare Occurrence of Secondary CML After AML: Case Study
Novel Treatment Under Study in Transplantation-Eligible Patients With AML
Early Results With Eftozanermin Alfa Plus Venetoclax in AML

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.